Article
NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.
Frontiers in immunology - 1 Jan 2022
Li Hongxia, Zhang Qin, Duan Qianqian, Tan Yuan, Sun Tingting, Qi Chuang
Abstract excerpt
Background: NRAS wildtype melanoma accounts for approximately 80% of melanomas. Previous studies have shown that NRAS wildtype melanoma had higher response rates and better prognoses than NRAS-mutant patients following immunotherapy, while as major actors in tumor cells and tumor microenvironment (TME), the association between NOTCH family genes and response to immunotherapy in NRAS wildtype melanoma remains...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.